Published in Vaccine on January 01, 1992
Immunity to murine chlamydial genital infection. Infect Immun (2002) 4.64
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 4.49
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A (1995) 2.63
Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun (1997) 2.49
Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun (1996) 2.14
Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun (1995) 2.04
Oral microbial ecology and the role of salivary immunoglobulin A. Microbiol Mol Biol Rev (1998) 1.81
Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun (1993) 1.78
Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med (1994) 1.55
Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun (1994) 1.51
Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect Immun (1996) 1.50
Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A (2006) 1.49
Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol (2011) 1.47
Loss of upper respiratory tract immunity with parenteral feeding. Ann Surg (1996) 1.47
Induction of B cell responses in the stomach of Helicobacter pylori- infected subjects after oral cholera vaccination. J Clin Invest (1998) 1.47
Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect Immun (1994) 1.43
A murine model of chronic mucosal colonization by Pseudomonas aeruginosa. Infect Immun (1992) 1.41
Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol (1996) 1.33
Killing of Streptococcus pneumoniae by capsular polysaccharide-specific polymeric IgA, complement, and phagocytes. J Clin Invest (1999) 1.32
Monoclonal immunoglobulin A derived from peritoneal B cells is encoded by both germ line and somatically mutated VH genes and is reactive with commensal bacteria. Infect Immun (1996) 1.30
Products of enteropathogenic Escherichia coli inhibit lymphocyte activation and lymphokine production. Infect Immun (1995) 1.30
Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague. Infect Immun (1995) 1.29
Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun (1998) 1.29
A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect Immun (1995) 1.29
Immunoglobulin G antibodies in human vaginal secretions after parenteral vaccination. Infect Immun (1994) 1.28
Gastric invasion by Trypanosoma cruzi and induction of protective mucosal immune responses. Infect Immun (1996) 1.27
Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv Drug Deliv Rev (2012) 1.25
Route and type of nutrition influence mucosal immunity to bacterial pneumonia. Ann Surg (1999) 1.25
Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog (2010) 1.22
Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun (1995) 1.21
Immunization against rabies with plant-derived antigen. Proc Natl Acad Sci U S A (1998) 1.21
Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A. Infect Immun (1999) 1.20
Chlamydial colonization of multiple mucosae following infection by any mucosal route. Infect Immun (1999) 1.19
Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun (2004) 1.17
Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization. Infect Immun (1996) 1.16
Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen. Infect Immun (2005) 1.13
Immunity to Cryptosporidium muris infection in mice is expressed through gut CD4+ intraepithelial lymphocytes. Infect Immun (1996) 1.11
Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun (1999) 1.09
Rectal immunization for induction of specific antibody in the genital tract of women. J Clin Immunol (1997) 1.08
Heat shock- and alkaline pH-induced proteins of Campylobacter jejuni: characterization and immunological properties. Infect Immun (1994) 1.07
Inflammation and clearance of Chlamydia trachomatis in enteric and nonenteric mucosae. Infect Immun (2001) 1.06
Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect Immun (1996) 1.06
Past, present, and future technologies for oral delivery of therapeutic proteins. J Pharm Sci (2008) 1.05
A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine (2008) 1.05
CXCL12 and CXCR4 expression by human gingival fibroblasts in periodontal disease. Clin Exp Immunol (2005) 1.05
Surface display of the cholera toxin B subunit on Staphylococcus xylosus and Staphylococcus carnosus. Appl Environ Microbiol (1997) 1.04
Homing commitment of lymphocytes activated in the human gastric and intestinal mucosa. Gut (2001) 1.03
Human intestinal M cells display the sialyl Lewis A antigen. Infect Immun (1999) 1.01
Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis. Proc Natl Acad Sci U S A (1996) 0.99
Stimulation of antigen-specific T- and B-cell memory in local as well as systemic lymphoid tissues following oral immunization with cholera toxin adjuvant. Immunology (1993) 0.99
Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus. Immunology (2002) 0.98
Intranasal immunization with Toxoplasma gondii SAG1 induces protective cells into both NALT and GALT compartments. Infect Immun (2000) 0.98
Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice. PLoS One (2012) 0.97
Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A of Streptococcus sobrinus: dose response and induction of protective humoral responses in rats. Infect Immun (1995) 0.96
Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infect Immun (1999) 0.96
A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys. Infect Immun (1994) 0.96
Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review. Int J Nanomedicine (2012) 0.96
Rotavirus-specific intestinal immune response in mice assessed by enzyme-linked immunospot assay and intestinal fragment culture. Clin Diagn Lab Immunol (1994) 0.96
Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. J Virol (2013) 0.95
Protein crystallography and infectious diseases. Protein Sci (1994) 0.95
Nutrition and gut immunity. Surg Clin North Am (2011) 0.94
The mouth: a gateway or a trap for HIV? AIDS (2010) 0.93
Quantitative analysis of age specific variation in the abundance of human female parotid salivary proteins. J Proteome Res (2009) 0.92
Hochuekkito, a Kampo (traditional Japanese herbal) Medicine, Enhances Mucosal IgA Antibody Response in Mice Immunized with Antigen-entrapped Biodegradable Microparticles. Evid Based Complement Alternat Med (2007) 0.91
Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization. J Virol (2001) 0.91
Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology (1993) 0.91
Intranasal immunization with recombinant Ascaris suum 14-kilodalton antigen coupled with cholera toxin B subunit induces protective immunity to A. suum infection in mice. Infect Immun (2001) 0.90
Small intestine mucosal immune system response to injury and the impact of parenteral nutrition. Surgery (2010) 0.90
Oral immunization with a recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin elicits an intestinal secretory immunoglobulin A response that has in vitro adherence inhibition activity. Infect Immun (1996) 0.89
CCL28 induces mucosal homing of HIV-1-specific IgA-secreting plasma cells in mice immunized with HIV-1 virus-like particles. PLoS One (2011) 0.89
CD8-deficient mice exhibit augmented mucosal immune responses and intact adjuvant effects to cholera toxin. Immunology (1996) 0.89
Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens. Infect Immun (1999) 0.89
The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect Immun (2011) 0.88
Vaccine adjuvants - Current status and prospects on controlled release adjuvancity. Saudi Pharm J (2011) 0.88
Protection against nontypeable Haemophilus influenzae challenges by mucosal vaccination with a detoxified lipooligosaccharide conjugate in two chinchilla models. Microbes Infect (2009) 0.87
Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses. Ther Clin Risk Manag (2009) 0.87
Antibody in middle ear fluid of children originates predominantly from sera and nasopharyngeal secretions. Clin Vaccine Immunol (2012) 0.86
Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization. Infect Immun (2000) 0.86
Human gastric B cell responses can be induced by intestinal immunisation. Gut (2001) 0.86
Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect Immun (1999) 0.86
Induction of immune responses in mice after intragastric administration of Lactobacillus casei producing porcine parvovirus VP2 protein. Appl Environ Microbiol (2007) 0.86
Biodegradable nanoparticle-entrapped vaccine induces cross-protective immune response against a virulent heterologous respiratory viral infection in pigs. PLoS One (2012) 0.86
Enteral feeding preserves mucosal immunity despite in vivo MAdCAM-1 blockade of lymphocyte homing. Ann Surg (2003) 0.85
Characteristic Immune Response in Peyer's Patch Cells Induced by Oral Administration of Bifidobacterium Components. Cytotechnology (2005) 0.85
Identification of the Entamoeba histolytica galactose-inhibitable lectin epitopes recognized by human immunoglobulin A antibodies following cure of amebic liver abscess. Infect Immun (2004) 0.85
Efficacy of oral vaccination against the murine intestinal parasite Trichuris muris is dependent upon host genetics. Infect Immun (1995) 0.85
Nasal immunization with homogenate and peptide antigens induces protective immunity against Trichinella spiralis. Infect Immun (2002) 0.84
Mucosal memory B cells retain the ability to produce IgM antibodies 2 years after oral immunization. Immunology (1995) 0.84
Expression of cholera toxin B subunit and the B chain of human insulin as a fusion protein in transgenic tobacco plants. Plant Cell Rep (2005) 0.84
Food fight! Parenteral nutrition, enteral stimulation and gut-derived mucosal immunity. Langenbecks Arch Surg (2008) 0.83
Beneficial effect of enteral feeding. Gastrointest Endosc Clin N Am (2007) 0.83
Mouse models for the study of mucosal vaccination against otitis media. Vaccine (2008) 0.83
Proinflammatory cytokine surge after injury stimulates an airway immunoglobulin a increase. J Trauma (2010) 0.83
Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance. Infect Immun (2001) 0.83
Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen. Infect Immun (1999) 0.82
Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin Diagn Lab Immunol (2002) 0.82
Construction of recombinant Lactobacillus casei efficiently surface displayed and secreted porcine parvovirus VP2 protein and comparison of the immune responses induced by oral immunization. Immunology (2007) 0.81
The immune modifying effects of amino acids on gut-associated lymphoid tissue. J Anim Sci Biotechnol (2013) 0.81
Levels of parotid and submandibular/sublingual salivary immunoglobulin A in response to experimental gingivitis in humans. Clin Oral Investig (2004) 0.81
The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol (1987) 5.30
Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol (2008) 5.28
Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol (1987) 4.53
Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med (1989) 3.28
Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int (2007) 3.17
Antibodies to native and denatured collagens in sera of patients with rheumatoid arthritis. Arthritis Rheum (1976) 2.97
Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol (1995) 2.87
Ingestion of Streptococcus mutans induces secretory immunoglobulin A and caries immunity. Science (1976) 2.78
Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest (1999) 2.77
Selective induction of an immune response in human external secretions by ingestion of bacterial antigen. J Clin Invest (1978) 2.64
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med (1993) 2.62
Pathogenic species of the genus Haemophilus and Streptococcus pneumoniae produce immunoglobulin A1 protease. Infect Immun (1979) 2.57
Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol Rev (1988) 2.50
IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc Natl Acad Sci U S A (1987) 2.37
Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J Immunol (1996) 2.30
Secretory component of epithelial cells is a surface receptor for polymeric immunoglobulins. J Exp Med (1978) 2.26
IgA1 proteases from Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, and Streptococcus sanguis: comparative immunochemical studies. J Immunol (1980) 2.23
A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A (1997) 2.07
Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine (1995) 2.06
An enzymatic method for preparation of dissociated murine Peyer's patch cells enriched for macrophages. J Immunol Methods (1982) 2.06
Immunoglobulin M and secretory immunoglobulin A: presence of a common polypeptide chain different from light chains. Science (1971) 2.03
IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med (1988) 2.02
Immunoglobulin A (IgA). Methods Enzymol (1985) 1.94
Accessory cells in murine Peyer's patch. I. Identification and enrichment of a functional dendritic cell. J Exp Med (1983) 1.92
A novel two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells. J Immunol Methods (1988) 1.91
Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int (1997) 1.88
Protection against vaginal SIV transmission with microencapsulated vaccine. Science (1993) 1.86
Naturally occurring secretory immunoglobulin A antibodies to Streptococcus mutans in human colostrum and saliva. Infect Immun (1976) 1.85
Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release (2001) 1.85
IgA-induced eosinophil degranulation. J Immunol (1989) 1.82
Synergistic effect of IL-4 and IFN-gamma on the expression of polymeric Ig receptor (secretory component) and IgA binding by human epithelial cells. J Immunol (1990) 1.82
Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells. J Immunol (1988) 1.80
Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J Clin Microbiol (1985) 1.80
Distribution of IgA1-, IgA2-, and J chain-containing cells in human tissues. J Immunol (1984) 1.78
Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun (1993) 1.78
Regulation of IgA synthesis and immune response by T cells and interleukins. J Clin Immunol (1989) 1.76
Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol (1996) 1.76
Detection of individual mouse splenic T cells producing IFN-gamma and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. J Immunol Methods (1990) 1.74
Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol (1994) 1.73
Murine model for evaluation of protective immunity to influenza virus. Vaccine (1993) 1.73
Tissue origins of human polymeric and monomeric IgA. J Immunol (1982) 1.73
Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol (1994) 1.72
Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit. Infect Immun (1996) 1.71
Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest (1986) 1.70
Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses. J Exp Med (1999) 1.69
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Characterization of antibodies to the native human collagens and to their component alpha chains in the sera and the joint fluids of patients with rheumatoid arthritis. Immunochemistry (1976) 1.67
Analysis of Th1 and Th2 cells in murine gut-associated tissues. Frequencies of CD4+ and CD8+ T cells that secrete IFN-gamma and IL-5. J Immunol (1990) 1.67
Systemically derived large intestinal CD4(+) Th2 cells play a central role in STAT6-mediated allergic diarrhea. J Clin Invest (2000) 1.66
The human IgA system: a reassessment. Clin Immunol Immunopathol (1986) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology (1999) 1.63
Studies on human secretory immunoglobulin A. II. Subunit structure. J Immunol (1972) 1.62
Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med (1997) 1.61
Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis (2000) 1.61
Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. J Immunol (1999) 1.60
Secretory immunoglobulin A carries oligosaccharide receptors for Escherichia coli type 1 fimbrial lectin. Infect Immun (1990) 1.60
Regulation of host immune responses by modification of Salmonella virulence genes. Nat Med (1998) 1.59
Novel function for intestinal intraepithelial lymphocytes. Murine CD3+, gamma/delta TCR+ T cells produce IFN-gamma and IL-5. J Immunol (1991) 1.58
Anticaries effects of polyphenolic compounds from Japanese green tea. Caries Res (1991) 1.57
IgA subclasses. Monogr Allergy (1986) 1.57
Cytokine profiles of bronchoalveolar lavage cells from mice with influenza pneumonia: consequences of CD4+ and CD8+ T cell depletion. Reg Immunol (1993) 1.56
Ferredoxin-dependent chloroplast enzymes. Biochim Biophys Acta (1991) 1.55
Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J Med Primatol (1992) 1.54
Immunoglobulin A subclass distribution of naturally occurring salivary antibodies to microbial antigens. Infect Immun (1985) 1.53
Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin Exp Immunol (1996) 1.51
Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect Immun (1996) 1.50
Role of serum IgA. Hepatobiliary transport of circulating antigen. J Exp Med (1981) 1.49
New perspectives in vaccine development: mucosal immunity to infections. Infect Agents Dis (1993) 1.48
Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum Gene Ther (1995) 1.48
Concept of the local and common mucosal immune response. Adv Exp Med Biol (1978) 1.46
Ventilator-induced lung injury is associated with neutrophil infiltration, macrophage activation, and TGF-beta 1 mRNA upregulation in rat lungs. Anesth Analg (2001) 1.46
Virulence of Streptococcus mutans: comparison of the effects of a coupling sugar and sucrose on certain metabolic activities and cariogenicity. Infect Immun (1978) 1.46
A 'safe-site' for Salmonella typhimurium is within splenic polymorphonuclear cells. Microb Pathog (1992) 1.44
Immunoregulatory functions for murine intraepithelial lymphocytes: gamma/delta T cell receptor-positive (TCR+) T cells abrogate oral tolerance, while alpha/beta TCR+ T cells provide B cell help. J Exp Med (1992) 1.44
Production of predominantly polymeric IgA by human peripheral blood lymphocytes stimulated in vitro with mitogens. J Exp Med (1980) 1.44
CD4+ T-cell population mediates development of inflammatory bowel disease in T-cell receptor alpha chain-deficient mice. Gastroenterology (1997) 1.44
Biodegradable microspheres: vaccine delivery system for oral immunization. Curr Top Microbiol Immunol (1989) 1.44
Purification and certain properties of a bacteriocin from Streptococcus mutans. Infect Immun (1982) 1.40
In vivo immune response to a T-cell-dependent antigen by cultures of disassociated murine Peyer's patch. Proc Natl Acad Sci U S A (1982) 1.39
Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res Hum Retroviruses (1998) 1.38
Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun (1998) 1.36
Secretory immune system of the female reproductive tract: I. Immunoglobulin and secretory component-containing cells. Obstet Gynecol (1988) 1.36
Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections. Infect Immun (1999) 1.36
Presence of antibodies specific to cartilage-type collagen in rheumatoid synovial tissue. Clin Exp Immunol (1975) 1.35
gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med (1996) 1.35
Properties of immunoglobulin A in serum of individuals with liver diseases and in hepatic bile. Gastroenterology (1982) 1.34
Alternate mucosal immune system: organized Peyer's patches are not required for IgA responses in the gastrointestinal tract. J Immunol (2000) 1.32
Assay of human IgA subclass antibodies in serum and secretions by means of monoclonal antibodies. J Immunol Methods (1986) 1.32